General
Preferred name
ENOXIMONE
Synonyms
Enoximonum ()
Enoximona ()
Perfan ()
MDL 17,043 ()
MDL-17043 ()
P&D ID
PD002748
CAS
77671-31-9
Tags
available
drug
First approval
1988
Drug indication
Congestive heart failure
Cardiovascular disease
Drug Status
approved
investigational
Max Phase
3.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Enoximone is a selective phosphodiesterase inhibitor, targeting PDE3 subtypes . It is a cardiotonic agent . (GtoPdb)
DESCRIPTION Enoximone is an inotropic vasodilating agent and a selective and orally active phosphodiesterase III (PDE3) inhibitor with an IC50 of 5.9 ¦ÌM. Enoximone induces vasodilatation and increases intracellular levels of cAMP by inhibiting cGMP-inhibited PDE. Enoximone also exhibits PDE4 inhibitory effect with an IC50 of 21.1 ¦ÌM for myocardial PDE4A. Enoximone has the potential for congestive heart failure research and has bronchodilatory, antiasthma and anti-inflammatory effects[1][2][3].
PRICE 73
DESCRIPTION PDE inhibitor (non-selective) (Tocris Bioactive Compound Library)
DESCRIPTION Selective phosphodiesterase III (PDE III) inhibitor (LOPAC library)
DESCRIPTION Enoximone is a selective phosphodiesterase III (PDE3) inhibitor. It can be used for the treatment of heart failure. (BOC Sciences Bioactive Compounds)
DESCRIPTION Enoximone is a selective inhibitor of phosphodiesterase III (PDE3), with treatment of congestive heart failure. (TargetMol Bioactive Compound Library)
Cell lines
0
Organisms
3
Compound Sets
19
BOC Sciences Bioactive Compounds
enoximone-cas-77671-31-9-item-77043
Cayman Chemical Bioactives
30868
ChEMBL Drugs
CHEMBL249856
Drug Repurposing Hub
DrugBank
DB04880
DrugBank Approved Drugs
DB04880
DrugCentral
1014
DrugCentral Approved Drugs
1014
DrugMAP
DMQVZJD
DrugMAP Approved Drugs
DMQVZJD
DrugMatrix
Guide to Pharmacology
9063
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL249856
MedChem Express Bioactive Compound Library
HY-B1639
NPC Screening Collection
ReFrame library
TargetMol Bioactive Compound Library
T8462
Tocris Bioactive Compound Library
1693
External IDs
31
Properties
(calculated by RDKit )
Molecular Weight
248.06
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
2
Rotatable Bonds
3
Ring Count
2
Aromatic Ring Count
2
cLogP
1.96
TPSA
65.72
Fraction CSP3
0.17
Chiral centers
0.0
Largest ring
6.0
QED
0.64
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
PDE III
Target
PDE3
phosphodiesterase
PDE3A
Phosphodiesterase (PDE)
Primary Target
Phosphodiesterases
MOA
Inhibitor
phosphodiesterase inhibitor
Indication
congestive heart failure
Pathway
Metabolism
Metabolic Enzyme/Protease
Therapeutic Class
Cardiotonic Agents
Solubility
DMSO: soluble28 mg/mL
Source data